Form DEFA14C - Additional information statement materials, definitive:
SEC Accession No. 0001193125-20-061683
Filing Date
2020-03-04
Accepted
2020-03-04 16:31:58
Documents
7
Effectiveness Date
2020-03-04

Document Format Files

Seq Description Document Type Size
1 DEFA14C d895181ddefa14c.htm DEFA14C 32517
2 GRAPHIC g895181g15i89.jpg GRAPHIC 8375
3 GRAPHIC g895181g23z34.jpg GRAPHIC 8926
4 GRAPHIC g895181g30y58.jpg GRAPHIC 8414
5 GRAPHIC g895181g36y78.jpg GRAPHIC 9271
6 GRAPHIC g895181g57p10.jpg GRAPHIC 8400
7 GRAPHIC g895181g69m08.jpg GRAPHIC 8379
  Complete submission text file 0001193125-20-061683.txt   73307
Mailing Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210
Business Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210 617-207-0202
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

EIN.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14C | Act: 34 | File No.: 001-38137 | Film No.: 20687642
SIC: 2834 Pharmaceutical Preparations